The WHO’s SOLIDARITY clinical trial evaluated remdesivir and three other drugs in 11,266 hospitalized COVID-19 patients and found that none of the drugs “substantially affected mortality” or decreased the need to ventilate patients, reported the Financial Times.
Veklury (remdesivir; GS-5734) is a nucleotide analog with broad-spectrum antiviral activity. Gilead’s Veklury has demonstrated in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are also coronaviruses, and are structurally similar to SARS-CoV-2, which causes COVID-19.
Gilead Sciences, Inc. announced on October 22, 2020, that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury® (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization.
On May 12, 2020, Mylan N.V. announced a license agreement signed with Gilead, to manufacture and distribute Veklury (remdesivir) in 127 low- and middle-income countries, including India. In India, Mylan launched the drug under the brand name DESREM.
Gilead Science first received a patent (US9724360B2) for the drug as a treatment for Ebola in 2017. In fall 2015, Gilead applied for two patents for remdesivir, one for combating coronaviruses and another for filoviruses, the family of pathogens that includes Ebola. Both were approved in spring 2019. Gilead Science, Inc. is located in Foster City.